Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Prog...( Phase III Clinical Trial of Acetav...),Health

Phase III Clinical Trial of Acetavance(TM) for the Treatment of Fever

Achieves Primary Endpoint

Phase III Clinical Trial of Omigard(TM) Completes Patient Enrollment

SAN DIEGO, May 6 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today reported financial results for the quarter ended March 31, 2008 and provided an update on the clinical development programs for its product candidates Acetavance(TM), an intravenous formulation of acetaminophen, and Omigard(TM), a topical antimicrobial gel.

The company announced that a Phase III clinical trial of Acetavance successfully met its primary endpoint of achieving a more rapid onset of action in the treatment of fever compared to oral acetaminophen. In addition, Cadence announced that it completed its goal of enrolling 1,850 patients in its Phase III clinical trial of Omigard for the prevention of catheter-related infections.

"We are very pleased with the outcome of our second Phase III clinical trial for the treatment of fever in adults. In addition to the positive data from our first Phase III clinical trial of Acetavance in fever announced earlier this year, we believe that the results of this study further strengthen the value proposition for Acetavance," said Ted Schroeder, President and Chief Executive Officer of Cadence. "We believe that there is a significant unmet need among patients and physicians in the hospital setting for a safe and effective treatment for pain and fever, particularly in cases where patients cannot take oral medication or require a mor
'/>"/>